Belite Bio 宣布,将在美国视网膜专家学会 (ASRS) 年会上进行口头报告,重点展示其药物Tinlarebant在治疗1型Stargardt病的三期临床试验中取得的额外积极次要终点数据。
Belite Bio 宣布,将在美国视网膜专家学会 (ASRS) 年会上进行口头报告,重点展示其药物Tinlarebant在治疗1型Stargardt病的三期临床试验中取得的额外积极次要终点数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.